Genmab's Arzerra shows first-line promise in chronic lymphocytic leukaemia
This article was originally published in Scrip
Executive Summary
Genmab/GlaxoSmithKline's anti-CD20 monoclonal antibody drug Arzerra (ofatumumab) has shown promising response rates in a Phase II trial testing two doses of the drug in combination with fludarabine and cyclophosphamide (FC) chemotherapy in previously untreated chronic lymphocytic leukaemia (CLL).